We welcome participation from all primary care centres in Birmingham and Black Country PCTs. If your practice is interested in taking part, or you would like to find out more information, please contact Dr Rhiannon Pursall on r.pursall@bham.ac.uk, 0121 414 4707.
Trial recruitment
How many patients are involved?
Phase I: We aim to recruit 40 patients, with 10 patients being randomised into each treatment group. Patients will be recruited from NHS primary care practices within Birmingham and Black Country, and from the Thousand Elders group of volunteers at the Wellcome Trust clinical Research Facility.
Phase II: We aim to recruit recruit 220 patients and randomise into two treatment arms. Patients will be recruited from NHS primary care practices within Birmingham and Black Country, and from the Thousand Elders group of volunteers at the Wellcome Trust clinical Research Facility.
Who can enter?
Phase I: Healthy people aged 65 years and above, without significant chronic illness and not taking certain medication that interferes with Valaciclovir. Participants must also test positive at screening for CMV, be HLA-type A1, A2, B7 or B8, and have CD4+ and/or CD8+ CMV-specific immune response of at least 0.2% of the total CD4+ and CD8+ T cell pools respectively. Must also have predicted eGFR>50ml/min and LFT in normal range.
Phase II: Healthy people aged 65 years and above, without significant chronic illness and not taking certain medication, and whom test positive for the presence of CMV-specific antibody. Participants must also have a predicted eGFR>50ml/min and LFT in normal range.